EU funds clinical software research to detect breast cancer
The European Union (EU) has invested EUR3.1 million ($3.97 million U.S.) through the HAMAM project for developing clinical software tools that integrate imaging and quantitative data and combine it with personalized risk profiles for developing breast cancer, based on genetic information and family history.

The project will seek to develop a prototype workstation to help diagnose breast cancer by integrating images resulting from x-ray, mammography, tomosynthesis, MRI, 2D/3D ultrasound and positron emission mammography as well as patient  information.

The project’s clinical advisory board involved leading experts in breast cancer diagnosis from six EU member states (Belgium, Germany, Italy, the Netherlands, Sweden and the U.K.), as well as from the U.S. Clinical tests will be undertaken in hospitals in Berlin, in Dundee, U.K. and in Nijmegen, the Netherlands, added EU.

The results of the three-year HAMAM (Highly Accurate Breast Cancer Diagnosis through Integration of Biological Knowledge, Novel Imaging Modalities and Modelling) project which started in 2008 will be presented at the European Commission's ICT 2010 conference in Brussels, Sept. 27 to 29.